Merck & Co. stock
Price history
+59.00% over the period1 year: from $92.93 (November 13, 2025) to $147.76 (November 13, 2026), +59.00%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 13, 2026 | $147.76 |
| October 30, 2026 | $149.52 |
| September 30, 2026 | $145.31 |
| August 31, 2026 | $147.76 |
| July 31, 2026 | $130.20 |
| June 30, 2026 | $128.50 |
| May 29, 2026 | $118.72 |
| April 30, 2026 | $109.18 |
| March 31, 2026 | $120.29 |
| February 27, 2026 | $123.82 |
| January 30, 2026 | $110.27 |
| December 31, 2025 | $105.26 |
| November 28, 2025 | $104.83 |
| November 13, 2025 | $92.93 |
At a glance
The company
Develops and markets pharmaceuticals for human health, vaccines, and veterinary medicines and health solutions
Latest results
Quarter to September 30, 2026 · EPS $2.49 (estimate $2.09)
TickerLandia's take on Merck & Co.
- Priced as usual relative to earnings: P/E on the latest fiscal year 20 vs a median of 23 over its last 9 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 148 vs 42 (+249%) in a group of 10.
- Strong point: Market momentum (84/100 in its group). Weak point: Growth (31/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−5.84% from the 52-week high
Analysts · 28 analysts
Average target$161.53+9.32% vs. price
Buy 19 · Hold 9 · Sell 0 · Buy
TickerLandia Fingerprint: Merck & Co.
Compared with similar companies: very strong momentum.
Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricehigh71
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 147.8 98 Forward P/E 16.5 52 EV/EBITDA 13.9 66 Price/book 8.12 69 Price/sales 5.41 70 Profitabilityaverage50
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 35.2% 74 Gross margin 75.2% 70 Net margin 3.6% 14 ROE 5.1% 19 ROA 11.3% 74 Earnings stabilityaverage42
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 5.4% 30 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 54 Growthlow31
How fast revenue and earnings are growing.
Metric Value Position in group Revenue growth (year over year) +4.70% 24 Earnings growth (year over year) −12.00% 31 Average revenue growth (3 years) +3.12% 38 Financial strengthaverage41
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.23 34 Interest coverage 18.0 54 Current ratio 1.35 46 Debt/equitycounts in reverse: lower means more financial strength 1.20 31 Dividendhigh79
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 37 years 90 Dividend yield 2.3% 48 Payout ratiopays out more than its earnings 343.4% 98 Market momentumvery strong84
How the stock has moved compared with the market.
Metric Value Position in group Distance from 200-day average +14.86% 81 1-year return +59.00% 91 Relative strength (3 months) +12.43% 78 Relative strength (6 months) +28.22% 85 Risklow21
How much the price swings.
Metric Value Position in group Volatility (60 days) 28.1% 33 Beta (1 year) 0.22 28 Maximum drawdown (12 months) 11.9% 3
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Merck & Co. is priced as in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Merck & Co.'s P/E today is 20.3, in line with the median of its last 9 fiscal years (22.8; between 14.5 and 61.7 from 2016 to 2025). Merck & Co.'s P/E (trailing 12 months): 147.8, +249% against the median of a group of 10 similar companies (42.3).
Compared with 10 similar companies
| Metric | Merck & Co. | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 147.8 | High | |
| Forward P/E | 16.5 | Middle | |
| Operating margin | 35.2% | Middle | |
| ROE | 5.1% | Middle | |
| Debt/equity | 1.20 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Merck & Co.. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$18.09B
Latest quarter · Q3 2026
Net income
$5.07B
Latest quarter · Q3 2026
Quarterly net margin
28.0%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- $364.26B
- P/E
- 147.8
- EPS
- $1.00
- Volume
- 6.5M
- Daily trading
- €1.28B
- Dividend yield
- 2.30%
- Last ex-dividend on September 15, 2026
How Merck & Co. is changing
All resultsRevenue grew 9.4% a year on average over the last 5 years
Operating margin rose from 34.6% to 37.6%
Profits turn into cash: free cash flow equal to 111% of net income
Returns
Merck & Co. returns with dividends
$1,000 invested in Merck & Co. 5 years ago, on November 15, 2021, would be worth $2,057 today with dividends reinvested: +105.66% in total, +15.53% per year. On price alone it would be $1,766 (+76.56%).
| Period | Merck & Co. | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +4.07% | −3.12% | $1,041 |
| 6 months | +30.24% | +1.58% | $1,302 |
| Year to date | +40.38% | +10.46% | $1,404 |
| 1 year | +63.69% | +12.23% | $1,637 |
| 3 years | +58.04% | +71.41% | $1,580 |
| 5 years | +105.66% | +61.48% | $2,057 |
| 10 years | +230.73% | +249.40% | $3,307 |
Over the last 6 months it has done better than 68% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Merck & Co.: technical analysis
Merck & Co. is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 5.6% below its highest close since January 2, 1990 ($156.45, August 25, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 53
- Between 30 and 70
- vs 200-session average
- +14.86%
Support and resistance
Price areas where Merck & Co. has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$153.44+3.84%4 touches, last on November 5, 2026
- Last price$147.76
- Support$142.56−3.52%2 touches, last on November 6, 2026
- Support$139.01−5.93%2 touches, last on October 28, 2026
- Support$131.01−11.33%2 touches, last on July 17, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.22
- Volatility (60 sessions, annualised)
- 28.1%
- Largest fall in the last year
- −11.90%
Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Merck & Co.: seasonality
Average monthly price change over 37 years
Over the last 37 years, the strongest month for Merck & Co. has been November: +3.40% on average, positive in 25 years out of 36. The weakest has been September: −0.77% on average, positive in 17 years out of 37.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +0.99% | +2.22% | 21 of 36 |
| February | −0.73% | −1.20% | 15 of 37 |
| March | −0.74% | +0.49% | 22 of 37 |
| April | +1.30% | +2.13% | 22 of 37 |
| May | +1.64% | +1.87% | 23 of 37 |
| June | +1.25% | +0.42% | 19 of 37 |
| July | −0.37% | −0.42% | 16 of 37 |
| August | +0.39% | −0.03% | 18 of 37 |
| September | −0.77% | −0.61% | 17 of 37 |
| October | +2.37% | +2.44% | 21 of 37 |
| November | +3.40% | +4.19% | 25 of 36 |
| December | +1.28% | +0.83% | 22 of 36 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Merck & Co. and its competitors
Customers for Merck & Co., Inc.'s human health medicines, vaccines and animal health products are spread across markets worldwide, with the United States and EMEA accounting for most of its revenue. The company sells prescription medicines and vaccines for human patients, including Keytruda, Gardasil, Januvia and Winrevair, and veterinary pharmaceuticals for livestock and companion animals, under brands such as Bravecto, Nobivac NXT and Bovilis. It also offers Allflex Livestock Intelligence solutions and has collaboration agreements with Daiichi Sankyo, AstraZeneca, Moderna and LaNova.
- Headquarters
- Rahway, United States
- Employees
- 73,000
- Founded
- 2000
- Chief executive
- Robert Davis
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Merck & Co.MRK | $364.26B | 35.2% | 147.8 | +30.24% |
| AbbVieABBV | $521.5B | 36.6% | 50.6 | +41.50% |
| AmgenAMGN | $251.89B | 34.1% | 27.0 | +38.41% |
| Gilead SciencesGILD | $208.48B | 38.2% | — | +26.33% |
| Johnson & JohnsonJNJ | $687.89B | 26.6% | 43.4 | +24.01% |
| PfizerPFE | $164.67B | 29.1% | 41.3 | +11.29% |
Same industry or related industries, similar size. Compare Merck & Co. with its competitors · Full profile
